Last update 08 May 2025

Allogeneic hematopoietic stem cell transplantation(Yake Biotechnology)

Overview

Basic Info

Drug Type
Hematopoietic stem cell therapy
Synonyms
Allo-HSCT(Yake Biotechnology)
Target-
Action-
Mechanism-
Therapeutic Areas
Congenital DisordersEndocrinology and Metabolic DiseaseHemic and Lymphatic Diseases+ [2]
Active Indication
Anemia, Diamond-BlackfanDyskeratosis CongenitaFanconi Anemia+ [1]
Inactive Indication-
Originator Organization
Shanghai Yake Biotechnology Co., LtdShanghai Yake Biotechnology Co., Ltd
Active Organization
Shanghai Yake Biotechnology Co., LtdShanghai Yake Biotechnology Co., Ltd
Inactive Organization-
License Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Allogeneic hematopoietic stem cell transplantation(Yake Biotechnology)
NCT06787560
/ RecruitingEarly Phase 1IIT
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases
100 Clinical Results associated with Allogeneic hematopoietic stem cell transplantation(Yake Biotechnology)
Login to view more data
100 Translational Medicine associated with Allogeneic hematopoietic stem cell transplantation(Yake Biotechnology)
Login to view more data
100 Patents (Medical) associated with Allogeneic hematopoietic stem cell transplantation(Yake Biotechnology)
Login to view more data
100 Deals associated with Allogeneic hematopoietic stem cell transplantation(Yake Biotechnology)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anemia, Diamond-BlackfanPhase 1
China
Shanghai Yake Biotechnology Co., LtdShanghai Yake Biotechnology Co., Ltd
31 Jan 2025
Dyskeratosis CongenitaPhase 1
China
Shanghai Yake Biotechnology Co., LtdShanghai Yake Biotechnology Co., Ltd
31 Jan 2025
Fanconi AnemiaPhase 1
China
Shanghai Yake Biotechnology Co., LtdShanghai Yake Biotechnology Co., Ltd
31 Jan 2025
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 1
China
Shanghai Yake Biotechnology Co., LtdShanghai Yake Biotechnology Co., Ltd
31 Jan 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free